Cannabinoids and oral cancer

This in vitro (laboratory) oral cancer study was published in the journal Cancers in October 2022, and examined the effects of low doses of D9-THC, D8-THC, and 6 other cannabinoids on models of human gingival carcinoma cell lines.

The study examined multiple indicators of cancer cell viability after exposure to a mixture of 8 different cannabinoids:

  1. Cannabidiol (CBD), 500 μg/mL
  2. Cannabigerol (CBG), 500 μg/mL
  3. Cannabinol (CBN), 500 μg/mL
  4. CBC (Cannabichromene), 500 μg/mL
  5. CBDV (Cannabidivarin), 500 μg/mL
  6. (-)-delta8-THC, 500 μg/mL
  7. (-)-delta9-THC, 500 μg/mL
  8. THCV, 500 μg/mL


The results are quite technical, and if you are interested, click the full text link below. But here are the main conclusions as quoted by the authors:

In summary, our study demonstrates that a mixture of cannabinoids particularly at a dose of 1 µg/mL was able to inhibit oral cancer cell proliferation through diverse mechanisms including apoptosis and autophagy.

Our findings provide evidence that cannabinoids at limited concentrations could serve as an effective therapeutic strategy to target human oral cancers.


The full text article is here.